The recent FDA approval of a GLP-1 receptor agonist therapy for adults with type 2 diabetes and chronic kidney disease (CKD) represents a pivotal step forward in evidence-based nephrology care. This milestone, which includes medications within the same class as Ozempic® (semaglutide), reflects growing recognition of the importance of guideline-directed medication therapy (GDMT) in slowing CKD progression and improving patient outcomes.

At Panoramic Health, this approval reinforces our commitment to integrating clinical research and data-driven insights across our national nephrology platform to advance the standard of kidney care. Our platform-wide Clinical Quality Improvement Program prioritizes the adoption of therapies proven to enhance renal outcomes, reduce hospitalizations, and support value-based performance.

The approval also underscores the critical role of clinical research in accelerating innovation and validating new treatment modalities. Pharmaceutical innovation continues to deliver a robust pipeline of promising CKD therapies that target metabolic, inflammatory, and cardiometabolic pathways linked to kidney decline. With an expansive network of nephrology practices and research-ready sites, Panoramic Health provides the data infrastructure, real-world patient diversity, and operational capabilities needed to support clinical research sponsors and practice

partners as they bring the next generation of CKD treatments to patients. Through our integrated care delivery model and quality analytics framework, we enable rapid translation of clinical evidence into practice, ensuring our physician partners remain aligned with the latest FDA-approved therapies and guideline updates.

Our model empowers practices to access population-level analytics, predictive modeling, and outcomes-based benchmarking, all designed to support precision prescribing and early intervention strategies that slow CKD progression. This alignment between clinical operations and research enables Panoramic Health to uniquely bridge the gap between innovation and implementation, supporting both regulatory compliance and patient safety.

In addition, our research infrastructure and national dataset offer a robust foundation for observational and interventional trials across multiple geographies and care settings. By connecting clinical insight, real-world data, and physician engagement, we help accelerate trial feasibility and execution, ensuring new therapies can be evaluated efficiently and responsibly.

Each element of our clinical quality strategy —from outcomes benchmarking and population health analytics to GDMT adherence —reflects a deliberate commitment to elevating kidney care through precision, scale, and collaboration. As new GLP-1a and adjunct therapies continue to move through clinical development and post-approval research, Panoramic Health stands ready to partner with biopharmaceutical sponsors and nephrology innovators seeking to accelerate therapy evaluation and adoption within real-world clinical settings. By bridging clinical research with practice-level implementation, we help transform discovery into measurable improvements in kidney health outcomes nationwide.

To learn more about how Panoramic Health partners with research sponsors and practice groups to advance clinical innovation in CKD, visit our Panoramic Science page.